🇦🇺 PF-06882961 (Cohorts 1 and 2) in Australia

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2) regulatory status in Australia.

Marketing authorisation

TGA

  • Status: approved

PF-06882961 (Cohorts 1 and 2) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Australia

Frequently asked questions

Is PF-06882961 (Cohorts 1 and 2) approved in Australia?

Yes. TGA has authorised it.

Who is the marketing authorisation holder for PF-06882961 (Cohorts 1 and 2) in Australia?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.